Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 10, 1996, Pages 3498-3504

  Jossart, Gregg H ^a   Epstein, Howard D ^a   Shaver, John K ^a   Weier, Heinz Ulrich ^c   Greulich, Karin M ^c   Tezelman, Serdar ^a   Grossman, Richard F ^a   Siperstein, Allan E ^a   Duh, Quan Yang ^b   Clark, Orlo H ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DNA PROBES; DNA, NEOPLASM; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10244232995     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.10.3498     Document Type: Article

References (39)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991 p53 mutations in human cancers. Science. 253:49-53.
2. Nigro JM, Baker SJ, Preisinger AC, et al. 1989 Mutations in the p53 gene occur in diverse human rumour types. Nature. 342:705-708.
3. Koshland Jr D. 1993 Molecule of the year [editorial]. Science. 262:
4. Harris CC, Hollstein M. 1993 Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1318-1327.
5. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D. 1995 Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene. 10:49-39.
6. Levine AJ, Momand J, Finlay CA. 1991 The p53 tumour suppressor gene. Nature. 351:453-456.
7. Milner J, Medcalf EA. 1991 Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell. 65:765-774.
8. Milner J, Medcalf EA, Cook AC. 1991 Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol. 11:12-19.
9. Knudson AG. 1993 Antioncogenes and human cancer. Proc Natl Acad Sci USA. 90:10914-10921.
10. Bennett WP, Hollstein MC, Metcalf RA, et al. 1992 p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 52:6092-6097.
11. Vahakangas KH, Samet JM, Metcalf RA, et al. 1992 Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 339:576-580.
12. Sozzi G, Miozzo M, Donghi R, et al. 1992 Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 52:6079-6082.
13. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS. 1993 Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res. 53:1783-1787.
14. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 91:179-184.
15. Ito T, Seyama T, Mizuno T, et al. 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52:1369-1371.
16. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 91:1753-1760.
17. Wright PA, Lemoine NR, Goretzki PE, et al. 1991 Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene. 6:1693-1697.
18. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. 1992 Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 52:5061-5064.
19. Ito T, Seyama T, Mizuno T, et al. 1993 Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res. 84:526-531.
20. Nakamura T, Yana I, Kobayashi T, et al. 1992 p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res. 83:1293-1298.
21. Dobashi Y, Sakamoto A, Sugimura H, et al. 1993 Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol. 17:375-381.
22. Zou M, Shi Y, Fand NR. 1993 p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab. 77:1054-1058.
23. Dobashi Y, Sugimura H, Sakamoto A, et al. 1994 Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagnostic Molecular Pathology. 3:9-14.
24. Cady B, Rossi R. 1988 An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 104:947-953.
25. Sambrook J, Maniatis T, Fritsch EF. 1989 Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, p.9.16-9.23.
26. Sheffield VC, Cox DR, Lerman LS, Myers RM. 1989 Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA. 86:232-236.
27. Fischer SG, Lerman LS. 1983 DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. Proc Natl Acad Sci USA. 80:1579-1583.
28. Borresen AL, Hovig E, Smith-Sorensen B, et al. 1991 Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA. 88:8405-8409.
29. Sanger F, Nicklen S, Coulson AR. 1977 DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 74:5463-5467.
30. Esrig ED, Groshen S, Freeman JA, et al. 1994 Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1259-1264.
31. McCreery T, Helentjaris T. 1994 Production of DNA hybridization probes with digoxigenin-modified nucleotides by random hexanucleotide priming. Methods in Molecular Biology. 28:73-76.
32. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. 1992 ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 89:5321-5325.
33. Matsumura K, Kallioniemi A, Kallioniemi O, et al. 1992 Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res. 52:3474-3477.
34. Ito T, Seyama T, Hayashi Y, Dohi K, Akiyama M. 1994 Unique association of p53 mutations with undifferentiated carcinoma of the thyroid. Nippon Rinsho. 52:1069-1074.
35. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond J, Wynford-Thomas D. 1993 Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinog. 7:83-88.
36. Sauter G, Deng G, Moch H, et al. 1994 Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol. 144:756-766.
37. Myers RM, Cox DR 1992 Mutation detection by PCR, GC-clamps, and denaturing gradient gel electrophoresis. In: Erlich HA, ed. PCR technology: principles and application for DNA amplification. 1st ed. New York: W. H. Freeman and Company; 71-88.
38. Wynford-Thomas D. 1992 P53 in tumour pathology: can we trust immunocytochemistry? [editorial]. J Pathol. 166:329-330.
39. Anderson MW, Reynolds SH, You M, Maronpot RM. 1992 Role of protooncogene activation in carcinogenesis. Environ Health Perspect. 98:13-24.